Merck Serono's Kuvan heads CHMP positive opinion list
This article was originally published in Scrip
The first drug therapy for phenylketonuria,Merck Serono's Kuvan (sapropterin dihydrochloride), was among three products granted positive opinions on initial marketing from the EU's CHMPat its latest meeting on September 22nd-25th.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.